vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
$34.69M
Mr. Paul J. Sekhri M.Sc., MSc
9.00
High Point, NC
Jul 30, 2015
-2.09
$-6.83
1.36
1.50
-112,606.67%
-42.15
0.21
-33.79
47,464.20
1.36
-90.38%
112.95%
Similar stocks (15)
Edgewise Therapeutics, Inc.
EWTX
Erasca, Inc.
ERAS
C4 Therapeutics, Inc.
CCCC
Pyxis Oncology, Inc.
PYXS
Generation Bio Co.
GBIO
Kronos Bio, Inc.
KRON
Immix Biopharma, Inc.
IMMX
Elevation Oncology, Inc.
ELEV
NeuroBo Pharmaceuticals, Inc.
NRBO
GeoVax Labs, Inc.
GOVX
Allarity Therapeutics, Inc.
ALLR
Phio Pharmaceuticals Corp.
PHIO
Quoin Pharmaceuticals, Ltd.
QNRX
NovaBay Pharmaceuticals, Inc.
NBY
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00576%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (15)
Edgewise Therapeutics, Inc.
EWTX
Erasca, Inc.
ERAS
C4 Therapeutics, Inc.
CCCC
Pyxis Oncology, Inc.
PYXS
Generation Bio Co.
GBIO
Kronos Bio, Inc.
KRON
Immix Biopharma, Inc.
IMMX
Elevation Oncology, Inc.
ELEV
NeuroBo Pharmaceuticals, Inc.
NRBO
GeoVax Labs, Inc.
GOVX
Allarity Therapeutics, Inc.
ALLR
Phio Pharmaceuticals Corp.
PHIO
Quoin Pharmaceuticals, Ltd.
QNRX
NovaBay Pharmaceuticals, Inc.
NBY
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00576%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%